Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
3 Beaten-Down Stocks That Could Roar Back in June
03:20pm, Wednesday, 17'th Jun 2026
June is shaping up as a stock-picker's month. Spring volatility has settled, and contrarian investors are scanning the wreckage for quality names trading well off their highs with identifiable recover
FTSE 100 Live: London stocks flat as miners and oilers fall, SpaceX wobbles
12:08pm, Wednesday, 17'th Jun 2026
FTSE 100 down 5 points to 10,489 UK CPI inflation remained at 2.8% Pound falls as no BoE hikes expected 4.07pm: BAT for Maga The benefits of political...
Ozempic Linked To Lower Risk Of Violence In New Study
11:45am, Wednesday, 17'th Jun 2026
The researchers said the findings are not causal and urged more research into whether GLP-1s reduce the risk of violence. Daniel Semenza, lead author of the study and director of research at the New J
FTSE 100 Live: London stocks flat as miners and oilers fall, SpaceX set to fly higher
08:53am, Wednesday, 17'th Jun 2026
FTSE 100 down 7 points to 10,487 UK CPI inflation remained at 2.8% Pound falls as no BoE hikes expected 12.52pm: Fed meeting keeping a lid on markets The...
Novo Nordisk to File Oral Wegovy in China
01:52pm, Tuesday, 16'th Jun 2026
Novo Nordisk (NVO) rose 0.27% intraday after CEO Mike Doustdar told reporters the company plans to submit oral Wegovy for Chinese regulatory approval "very soon
Hacking group claims major hack of Novo Nordisk and attempted $25 million extortion
01:47pm, Tuesday, 16'th Jun 2026
A cyber extortion group claimed on Tuesday to have stolen more than a terabyte of data from pharmaceutical giant Novo Nordisk and said it is exploring selling parts of the data after unsuccessfu
Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock?
01:00pm, Tuesday, 16'th Jun 2026
Eli Lilly currently leads the weight loss market. Novo Nordisk's newer launches could help it make up some ground.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
10:01am, Tuesday, 16'th Jun 2026
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk: I Was Fooled By The Market Again (Rating Upgrade)
09:10am, Tuesday, 16'th Jun 2026
Novo Nordisk has significantly regained the market's confidence as the Wegovy pill drives notable recovery and market share stabilization. NVO's international operations offset U.S. pricing pressures,
Novo Nordisk to seek regulatory approval for Wegovy pill in China soon, says CEO
02:00am, Tuesday, 16'th Jun 2026
Novo Nordisk plans to seek Chinese regulatory approval for its weight-loss pill "very soon," CEO Mike Doustdar said Tuesday, in a move to catch up with rival Eli �
How LLY Overtook NVO in GLP-1 Space & Offering LLY Options Trade
12:30pm, Monday, 15'th Jun 2026
The GLP-1 race "is not fair to call a race anymore," argues Scott Zari when comparing Eli Lilly (LLY) and Novo Nordisk (NVO), calling the former a clear winner. He explains how Eli Lilly pulled ahead
Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock?
11:41am, Monday, 15'th Jun 2026
NVO stock jumps 7% in a week on U.K. approval of oral Wegovy and positive commercial updates, but competition and 2026 pressure cloud near-term outlook.
Novo Nordisk: The Danish Empire Strikes Back
08:34am, Monday, 15'th Jun 2026
Novo Nordisk remains a 'strong buy' despite recent underperformance and challenging 2026 guidance, supported by long-term growth prospects. NVO's Q1 '26 adjusted sales and operating profit declined, b
NVO DCF Analysis: Intrinsic Value $90 vs Price $44
07:32am, Monday, 15'th Jun 2026
On June 15, 2026, we delve into the DCF analysis for Novo Nordisk AS (NVO), a company that has faced significant price fluctuations recently. The stock has seen
The Next Phase Of The Obesity Drug Race
02:00pm, Saturday, 13'th Jun 2026
Five years after Wegovy's FDA approval, the obesity drug market has evolved rapidly. Novo Nordisk and Eli Lilly introduced GLP-1 pills this year and others like Structure Therapeutics and Zealand Phar
